Search research articles
Contact Us
Filters
Showing results (21-30 of 36) with videos related to
Page
of 4
Sort By:
Gynecologic Oncology Reports
|
April 18, 2022
A phase II study of MK-2206, an AKT inhibitor, in uterine serous carcinoma
Elizabeth H Stover, Niya Xiong, Andrea P Myers, et al.
Nature Communications
|
September 23, 2021
A Replication stress biomarker is associated with response to gemcitabine versus combined gemcitabine and ATR inhibitor therapy in ovarian cancer
Panagiotis A Konstantinopoulos, Alexandre André B A da Costa, Doga Gulhan, et al.
Biorxiv : the Preprint Server for Biology
|
July 16, 2025
Paclitaxel-induced mitotic arrest results in a convergence of apoptotic dependencies that can be safely exploited by BCL-X<sub>L</sub> degradation to overcome cancer chemoresistance
Xingping Qin, Adam Presser, Lissah Johnson, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
April 20, 2022
Improved T-cell Immunity Following Neoadjuvant Chemotherapy in Ovarian Cancer
Min Liu, Nabihah Tayob, Livius Penter, et al.
JCO Precision Oncology
|
April 18, 2024
Randomized Phase II Study of Gemcitabine With or Without ATR Inhibitor Berzosertib in Platinum-Resistant Ovarian Cancer: Final Overall Survival and Biomarker Analyses
Panagiotis A Konstantinopoulos, Su-Chun Cheng, Elizabeth K Lee, et al.
The Prostate
|
January 27, 2022
Implementation of a prostate cancer-specific targeted sequencing panel for credentialing of patient-derived cell lines and genomic characterization of patient samples
Elizabeth H Stover, Coyin Oh, Paula Keskula, et al.
Cancer Cell
|
June 5, 2003
PKC412 overcomes resistance to imatinib in a murine model of FIP1L1-PDGFRα-induced myeloproliferative disease
Jan Cools, Elizabeth H Stover, Christina L Boulton, et al.
The New England Journal of Medicine
|
March 28, 2003
A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome
Jan Cools, Daniel J DeAngelo, Jason Gotlib, et al.
Gynecologic Oncology
|
May 20, 2025
Phase 2, two-stage study of avelumab and axitinib in patients with mismatch repair proficient recurrent or persistent endometrial cancer
Elizabeth K Lee, Niya Xiong, Carolyn Krasner, et al.
Nature Communications
|
January 27, 2025
A compendium of Amplification-Related Gain Of Sensitivity genes in human cancer
Veronica Rendo, Michael Schubert, Nicholas Khuu, et al.
Page
of 4
Search research articles
Search
Showing results (21-30 of 36) with videos related to
Sort By:
Page
of 4
Gynecologic Oncology Reports
|
April 18, 2022
A phase II study of MK-2206, an AKT inhibitor, in uterine serous carcinoma
Elizabeth H Stover, Niya Xiong, Andrea P Myers, et al.
Nature Communications
|
September 23, 2021
A Replication stress biomarker is associated with response to gemcitabine versus combined gemcitabine and ATR inhibitor therapy in ovarian cancer
Panagiotis A Konstantinopoulos, Alexandre André B A da Costa, Doga Gulhan, et al.
Biorxiv : the Preprint Server for Biology
|
July 16, 2025
Paclitaxel-induced mitotic arrest results in a convergence of apoptotic dependencies that can be safely exploited by BCL-X<sub>L</sub> degradation to overcome cancer chemoresistance
Xingping Qin, Adam Presser, Lissah Johnson, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
April 20, 2022
Improved T-cell Immunity Following Neoadjuvant Chemotherapy in Ovarian Cancer
Min Liu, Nabihah Tayob, Livius Penter, et al.
JCO Precision Oncology
|
April 18, 2024
Randomized Phase II Study of Gemcitabine With or Without ATR Inhibitor Berzosertib in Platinum-Resistant Ovarian Cancer: Final Overall Survival and Biomarker Analyses
Panagiotis A Konstantinopoulos, Su-Chun Cheng, Elizabeth K Lee, et al.
The Prostate
|
January 27, 2022
Implementation of a prostate cancer-specific targeted sequencing panel for credentialing of patient-derived cell lines and genomic characterization of patient samples
Elizabeth H Stover, Coyin Oh, Paula Keskula, et al.
Cancer Cell
|
June 5, 2003
PKC412 overcomes resistance to imatinib in a murine model of FIP1L1-PDGFRα-induced myeloproliferative disease
Jan Cools, Elizabeth H Stover, Christina L Boulton, et al.
The New England Journal of Medicine
|
March 28, 2003
A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome
Jan Cools, Daniel J DeAngelo, Jason Gotlib, et al.
Gynecologic Oncology
|
May 20, 2025
Phase 2, two-stage study of avelumab and axitinib in patients with mismatch repair proficient recurrent or persistent endometrial cancer
Elizabeth K Lee, Niya Xiong, Carolyn Krasner, et al.
Nature Communications
|
January 27, 2025
A compendium of Amplification-Related Gain Of Sensitivity genes in human cancer
Veronica Rendo, Michael Schubert, Nicholas Khuu, et al.
Page
of 4